Buffered creatine costs more, promises more, and claims to cause less bloating. So what happened when researchers took actual slices of muscle to check? At the manufacturer's recommended dose of 1.5 g/day, Kre-Alkalyn did not raise muscle creatine in any meaningful way, while plain creatine monohydrate did. Here is what the Texas A&M trial found, and what it means for your wallet.
The Study: Who, What, How Long
The paper, published in the Journal of the International Society of Sports Nutrition in 2012 by Jagim, Kreider and colleagues, is a double-blind, randomized controlled trial in 36 resistance-trained participants (about 20 years old, 82 kg, 14.7% body fat). It ran for 28 days.
Participants were split into three groups:
- CrM: creatine monohydrate (Creapure) at 20 g/day (4 x 5 g) for 7 days, then 5 g/day for 21 days.
- KA-L: Kre-Alkalyn at the manufacturer's recommended 1.5 g/day for 28 days.
- KA-H: Kre-Alkalyn at the same loading and maintenance doses as the monohydrate group.
Everyone kept their normal training. The researchers took vastus lateralis muscle biopsies, fasting blood samples, DEXA scans and Wingate anaerobic tests at days 0, 7 and 28. They also tested bench press and leg press 1RM at days 0 and 28.
The Headline Finding: The Muscle Creatine Numbers
Muscle biopsies are the gold standard for answering one question: did the creatine actually get into the muscle? Biopsy data came from a subgroup of 25 participants.
Creatine rose across all groups over time, but the group differences were not statistically significant (p = 0.46). Still, the pattern leaned toward monohydrate. Average changes in muscle free creatine at days 7 and 28 were:
- KA-L: -7.9 and +4.7 mmol/kg dry weight
- KA-H: +1.0 and +9.1 mmol/kg DW
- CrM: +11.3 and +22.3 mmol/kg DW
In a pairwise comparison, the change in the label-dose buffered group was -1.1 mmol/kg DW versus +11.2 mmol/kg DW for monohydrate (mean ± SEM; p = 0.053). That is a trend rather than a clean statistical win, and the individual numbers varied widely from person to person. But the key point stands. There was no sign that the buffered product loaded muscle better, and at the label dose it essentially did not move the needle.
Strength, Size and Power: No Edge for Buffered Creatine
The marketing pitch for buffered creatine is better retention and better training adaptations. The data did not back that up. There were no significant group-by-time differences in:
- Body mass, fat-free mass, fat mass, body fat percentage or total body water
- Bench press and leg press 1RM
- Wingate mean power, peak power or total work
Some measures changed over time, as you would expect during training, but no group pulled ahead of the others. The low-dose buffered group did not outperform monohydrate, and neither did the group that took buffered creatine at monohydrate-equivalent doses.
The Bloating Claim: Busted
One of Kre-Alkalyn's selling points is fewer side effects. The authors found no evidence of that. In fact, no side effects were reported at all, including in the monohydrate group taking a 20 g/day loading dose. Water retention is hard to defend as a monohydrate problem when total body water did not differ between groups.
Safety markers looked fine too:
- Serum creatinine rose in all groups, more with higher doses (p = 0.03). The increases were only 0.1 to 0.2 mg/dL, well within normal values for active people.
- LDL cholesterol dropped more in the monohydrate group during loading, then returned to baseline during maintenance.
- Blood lipids, bone and catabolism markers, electrolytes, and lymphocyte and red cell counts showed no significant group differences.
Caveats Worth Knowing
This is a small, 28-day study in young, trained participants. The biopsy results came from only 25 of the 36 people, and variability was large, which is why the key comparison landed at p = 0.053 rather than below 0.05. The data cannot tell us about long-term effects, older adults, women specifically, or clinical populations. What the study does show is that buffered creatine did not beat the cheaper, better-studied option on any measured outcome.
What This Means for You
Dose: Take 3 to 5 g/day of creatine monohydrate. The study used 5 g/day for maintenance, which fits that range. If you want faster saturation, an optional load of about 20 g/day (split into four 5 g servings) for 5 to 7 days is the protocol that raised muscle creatine most in this trial. Loading is optional, since daily low-dose use gets you there over a few weeks.
Timing: The study did not test timing, and the broader evidence suggests it matters far less than consistency. Take it whenever you will remember to, with food if it sits better with your stomach.
What to buy: Choose plain monohydrate, ideally a product using Creapure or another third-party-tested monohydrate. It is the form used in this study's comparison arm, and it is usually cheaper.
Who it is for: Lifters, sprinters and team-sport athletes looking for support with high-intensity work and strength training.
Who should skip it or ask a doctor first: Anyone with kidney disease or reduced kidney function, or on medications that affect the kidneys, should talk to a physician first. Creatine raises serum creatinine slightly, which can confuse lab interpretation. Pregnant or breastfeeding women and minors should also get medical advice.
Bottom Line
The study found no advantage for buffered creatine in muscle creatine, body composition, strength or power, and no reduction in side effects. At the 1.5 g/day label dose, the biopsy data showed essentially no rise in muscle creatine, while monohydrate's rise was clearly larger. Unless new, well-controlled evidence shows otherwise, the premium price buys you marketing, not performance.
